Retrospective cohort study of correlation between immune check point molecular inhibitor and response factor, side effect, and post treatment
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Multivariable analysis results elucidated with a nomogram were presented at the 20th World Conference on Lung Cancer.
- 10 Sep 2019 Results assessing prediction of patients outcomes from patients charecteristics (n=128) presented at the 20th World Conference on Lung Cancer.
- 01 Aug 2018 Results (n=201) published in the Anticancer Research.